Shortage of Tamiflu seen nationwide.

FDA confirms three new cases of PML linked to Tysabri.

The AP (9/22) reported that the FDA "says it confirmed three new cases of a potentially lethal brain inflammation linked to the multiple sclerosis drug Tysabri [natalizumab]." The reports "are the first confirmed new cases since June," and since mid-2006, there "have been 13 reported cases of progressive multifocal leukoencephalopathy, or PML." The AP adds that "the FDA says the risk appears to increase as patients remain on Tysabri" and all "the PML cases are linked to its use in multiple sclerosis."

The Wall Street Journal (9/23, Armstrong) also reports on how the cases of PML will affect Biogen Idec Inc., the maker of Tysabri, and its stock.

Shortage of Tamiflu seen nationwide.

The Tennessean (9/23, Sanchez) reports, "Public demand for" Tamiflu (oseltamivir) "has caused a shortage of the children's dosage" nationwide, and some pharmacies "have run out of Tamiflu in the liquid form." The Tennessean notes, "Until more liquid prescription can be manufactured, pharmacists must convert the adult dosage capsules into a liquid by following FDA-approved guidelines on mixing." Meanwhile, health officials "are concerned that if more liquid is not commercially made soon, the items needed for the makeshift version also could run short."